Ind-Swift Laboratories Q1 FY27 PAT at ₹24.44 Cr; Sells Punjab Land for ₹17.50 Cr
Ind-Swift Laboratories reported Q1 FY27 Standalone Net Profit of ₹24.44 Crore, up from ₹8.12 Crore YoY. EBITDA was ₹33.32 Crore. The company also approved the sale of 10 acres of land in Punjab for ₹17.50 Crore, with completion expected in nine months.
The positive financial results are a key driver. The sale of land, while not core to operations, provides a cash inflow and resolves an issue with an unsuitable asset. The financial impact is moderate.
The company reported a substantial increase in net profit and EBITDA year-on-year, indicating improved financial performance. The sale of land, while a disposal, is for a non-operational asset and the proceeds will be received over nine months.
Ind-Swift Laboratories Limited announced the outcome of its Board Meeting held on August 10, 2026, wherein the Board approved the Standalone and Consolidated Unaudited Financial Results for the quarter ended June 30, 2026.
The company reported a Standalone Net Profit of ₹24.44 Crore for the quarter, a significant increase from ₹8.12 Crore in the corresponding quarter of the previous year. The EBITDA for the quarter stood at ₹33.32 Crore, up from ₹8.44 Crore year-on-year.
Additionally, the Board approved the sale of approximately 10 acres of land located in Village Behra, Derabassi, Punjab, for a total consideration of ₹17.50 Crore. The land was initially purchased for setting up a manufacturing facility but was found unsuitable for a Finished Dosages facility due to international regulatory requirements. The transaction is expected to be completed within nine months.
The Board Meeting commenced at 3:00 PM and concluded at 4:30 PM.
What to do with a filing like this
Ind-Swift Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Ind-Swift Laboratories Limited. Read the original for the full detail.